Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Vanda Pharmaceuticals Inc
VNDA
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$4.03
-0.21
-4.95%
Dern. MÀJ: Oct 16, 6:10 PM
$4.02
-0.22
-5.29%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Vanda Pharmaceuticals Financials
Vanda Pharmaceuticals (VNDA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of $(0.46) per share from
Benzinga Newsdesk
PRO
Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.
Benzinga Newsdesk
Earnings Scheduled For May 6, 2026
Benzinga Insights
PRO
Vanda Pharmaceuticals Raises FY2026 Sales Guidance from $230.000M-$260.000M to $240.000M-$290.000M vs $257.202M Est
Benzinga Newsdesk
PRO
Vanda Pharma Q1 EPS $(0.82) Misses $(0.69) Estimate, Sales $51.718M Miss $54.978M Estimate
Benzinga Newsdesk
PRO
Vanda Pharmaceuticals Sees FY2026 Sales $230.000M-$260.000M vs $271.275M Est
Vanda Pharmaceuticals (NASDAQ:VNDA) sees FY2026 sales of $230.000 million-$260.000 million vs $271.275 million analyst estimate.
Benzinga Newsdesk
